Skip to main content

An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Celgene Corporation

Start Date

July 24, 2019

End Date

June 30, 2024
 

Administered By

Duke Cancer Institute

Awarded By

Celgene Corporation

Start Date

July 24, 2019

End Date

June 30, 2024